venBio Partners LLC acquired 5,914,720 shares of Achieve Life Sciences. This investment represents a 5.75% stake in the biopharmaceutical company. The position is valued at approximately $38.6 million.
Achieve Life Sciences now ranks as the fourth-largest holding in venBio’s investment portfolio. The move signals institutional conviction in Achieve’s lead product candidate, cytisinicline.
Achieve plans to resubmit its New Drug Application for the treatment. The company targets a potential U.S. commercial launch in the first half of 2027.